Development
Immunocore's IMC-S118AI Enters Phase 1 Trial as First-in-Class PD-1 Agonist for Type 1 Diabetes
Immunocore Holdings plc has registered a Phase 1 first-in-human clinical trial (NCT07493122) for IMC-S118AI, a bispecific soluble TCR–PD-1 agonist fusion...
MoonLake Immunotherapeutics' sonelokimab achieves positive Phase 2 results in axial spondyloarthritis trial
Switzerland-based MoonLake Immunotherapeutics announced positive topline results from the S-OLARIS Phase 2 trial evaluating sonelokimab in axial...
Pilatus Biosciences doses first patient with anti-CD36 antibody PLT012 in advanced solid tumors
Pilatus Biosciences has dosed the first patient in a Phase 1 clinical trial of PLT012, a humanized monoclonal antibody that blocks CD36-mediated fatty acid...
Dyne Therapeutics' z-rostudirsen shows cardiopulmonary improvements in Duchenne muscular dystrophy trial
Dyne Therapeutics, a Waltham, Massachusetts-based clinical-stage company, announced new cardiopulmonary data from the ongoing Phase I/II DELIVER trial of...
Novartis' iptacopan slows kidney function decline by 49% in Phase III IgA nephropathy trial
Novartis (SWX: NOVN) reported final two-year results from the Phase III APPLAUSE-IgAN study showing that iptacopan (Fabhalta) slowed kidney function decline...
Karyopharm's selinexor doubles spleen response in myelofibrosis but misses symptom endpoint in Phase III
Karyopharm Therapeutics (Nasdaq: KPTI) reported topline results from its Phase III SENTRY trial in myelofibrosis, showing that selinexor combined with...
UCB's bimekizumab beats risankizumab in first head-to-head psoriatic arthritis biologic trial
Brussels-based UCB announced topline results from BE BOLD, a Phase III trial comparing bimekizumab (BIMZELX) with risankizumab (SKYRIZI) in adults with...
Cbio advances novoleucel T-cell therapy into first-in-human trial for recurrent cervical cancer
Copenhagen-based Cbio A/S has received European regulatory clearance to initiate a first-in-human Phase I/IIa clinical trial of novoleucel, a T-cell therapy...
Xenon Pharmaceuticals' azetukalner achieves positive phase 3 results in focal onset seizures
Vancouver and Boston-based Xenon Pharmaceuticals announced positive topline results from the Phase 3 X-TOLE2 study of azetukalner, a KV7 potassium channel...
CStone Pharmaceuticals' CS2009 shows 90% response rate in first-line non-small cell lung cancer
CStone Pharmaceuticals, the Suzhou-based oncology company listed on the Hong Kong Stock Exchange, reported Phase I/II data for its CS2009 trispecific...
Theriva Biologics' VCN-01 gains FDA agreement on Phase III design for metastatic pancreatic cancer
Theriva Biologics (NYSE American: TOVX), a Rockville, Maryland–based clinical-stage company, announced that the US FDA has agreed to the proposed design of...
Genentech terminates phase II trial of GDC-8264 for cardiac surgery-associated acute kidney injury
Genentech, Inc., a wholly owned subsidiary of Hoffmann-La Roche, has terminated its Phase II GDC-8264 clinical trial evaluating the selective RIPK1...
BridgeBio's ribitol therapy BBP-418 shows 31-second walk improvement over placebo in phase 3 LGMD2I/R9 trial
BridgeBio Pharma has presented interim results from FORTIFY, its Phase 3 trial of oral BBP-418 in limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). The...
Sanofi's amlitelimab meets Phase III endpoints in atopic dermatitis with extended 12-week dosing interval
Sanofi (NASDAQ: SNY) reported Phase III data from three trials of amlitelimab in moderate-to-severe atopic dermatitis, showing that the anti-OX40L antibody...
Meiji Seika Pharma initiates phase I trial of ME3241, a PD-1 agonist antibody for autoimmune disease
Meiji Seika Pharma has initiated a Phase I clinical trial in Australia evaluating ME3241, an anti-PD-1 agonist monoclonal antibody intended for autoimmune...
The AllSci Brief
Systematic R&D and deal news. Daily.